1
|
Scharfstein J, Ramos PIP, Barral-Netto M. G Protein-Coupled Kinin Receptors and Immunity Against Pathogens. Adv Immunol 2017; 136:29-84. [PMID: 28950949 DOI: 10.1016/bs.ai.2017.05.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
For decades, immunologists have considered the complement system as a paradigm of a proteolytic cascade that, acting cooperatively with the immune system, enhances host defense against infectious organisms. In recent years, advances made in thrombosis research disclosed a functional link between activated neutrophils, monocytes, and platelet-driven thrombogenesis. Forging a physical barrier, the fibrin scaffolds generated by synergism between the extrinsic and intrinsic (contact) pathways of coagulation entrap microbes within microvessels, limiting the systemic spread of infection while enhancing the clearance of pathogens by activated leukocytes. Insight from mice models of thrombosis linked fibrin formation via the intrinsic pathway to the autoactivation of factor XII (FXII) by negatively charged "contact" substances, such as platelet-derived polyphosphates and DNA from neutrophil extracellular traps. Following cleavage by FXIIa, activated plasma kallikrein (PK) initiates inflammation by liberating the nonapeptide bradykinin (BK) from an internal domain of high molecular weight kininogen (HK). Acting as a paracrine mediator, BK induces vasodilation and increases microvascular permeability via activation of endothelial B2R, a constitutively expressed subtype of kinin receptor. During infection, neutrophil-driven extravasation of plasma fuels inflammation via extravascular activation of the kallikrein-kinin system (KKS). Whether liberated by plasma-borne PK, tissue kallikrein, and/or microbial-derived proteases, the short-lived kinins activate immature dendritic cells via B2R, thus linking the infection-associated innate immunity/inflammation to the adaptive arm of immunity. As inflammation persists, a GPI-linked carboxypeptidase M removes the C-terminal arginine from the primary kinin, converting the B2R agonist into a high-affinity ligand for B1R, a GPCR subtype that is transcriptionally upregulated in injured/inflamed tissues. As reviewed here, lessons taken from studies of kinin receptor function in experimental infections have shed light on the complex proteolytic circuits that, acting at the endothelial interface, reciprocally couple immunity to the proinflammatory KKS.
Collapse
Affiliation(s)
- Julio Scharfstein
- Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Center of Health Sciences (CCS), Cidade Universitária, Rio de Janeiro, Brazil.
| | - Pablo I P Ramos
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil
| | | |
Collapse
|
2
|
Dillenburg-Pilla P, Maria AG, Reis RI, Floriano EM, Pereira CD, De Lucca FL, Ramos SG, Pesquero JB, Jasiulionis MG, Costa-Neto CM. Activation of the kinin B1 receptor attenuates melanoma tumor growth and metastasis. PLoS One 2013; 8:e64453. [PMID: 23691222 PMCID: PMC3656876 DOI: 10.1371/journal.pone.0064453] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2012] [Accepted: 04/15/2013] [Indexed: 01/02/2023] Open
Abstract
Melanoma is a very aggressive tumor that does not respond well to standard therapeutic approaches, such as radio- and chemotherapies. Furthermore, acquiring the ability to metastasize in melanoma and many other tumor types is directly related to incurable disease. The B1 kinin receptor participates in a variety of cancer-related pathophysiological events, such as inflammation and angiogenesis. Therefore, we investigated whether this G protein-coupled receptor plays a role in tumor progression. We used a murine melanoma cell line that expresses the kinin B1 receptor and does not express the kinin B2 receptor to investigate the precise contribution of activation of the B1 receptor in tumor progression and correlated events using various in vitro and in vivo approaches. Activation of the kinin B1 receptor in the absence of B2 receptor inhibits cell migration in vitro and decreases tumor formation in vivo. Moreover, tumors formed from cells stimulated with B1-specific agonist showed several features of decreased aggressiveness, such as smaller size and infiltration of inflammatory cells within the tumor area, higher levels of pro-inflammatory cytokines implicated in the host anti-tumor immune response, lower number of cells undergoing mitosis, a poorer vascular network, no signs of invasion of surrounding tissues or metastasis and increased animal survival. Our findings reveal that activation of the kinin B1 receptor has a host protective role during murine melanoma tumor progression, suggesting that the B1 receptor could be a new anti-tumor GPCR and provide new opportunities for therapeutic targeting.
Collapse
Affiliation(s)
- Patricia Dillenburg-Pilla
- Department of Biochemistry and Immunology, Faculty of Medicine at Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
| | - Andrea G. Maria
- Department of Biochemistry and Immunology, Faculty of Medicine at Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
| | - Rosana I. Reis
- Department of Biochemistry and Immunology, Faculty of Medicine at Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
| | - Elaine Medeiros Floriano
- Departament of Pathology, Faculty of Medicine at Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
| | - Cacilda Dias Pereira
- Department of Biochemistry and Immunology, Faculty of Medicine at Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
| | - Fernando Luiz De Lucca
- Department of Biochemistry and Immunology, Faculty of Medicine at Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
| | - Simone Gusmão Ramos
- Departament of Pathology, Faculty of Medicine at Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
| | - João B. Pesquero
- Department of Biophysics, Federal University of São Paulo, São Paulo, Brazil
| | | | - Claudio M. Costa-Neto
- Department of Biochemistry and Immunology, Faculty of Medicine at Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
- * E-mail:
| |
Collapse
|
3
|
Jankowski V, Tölle M, Santos RAS, Günthner T, Krause E, Beyermann M, Welker P, Bader M, Pinheiro SVB, Sampaio WO, Lautner R, Kretschmer A, van der Giet M, Zidek W, Jankowski J. Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J 2011; 25:2987-95. [PMID: 21628446 DOI: 10.1096/fj.11-185470] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The family of angiotensin peptides has been steadily growing in recent years. Most are fragments of angiotensin II (Ang II) with different affinities to the known angiotensin receptors. Here, we describe a novel endogenous Ang II-like octapeptide in plasma from healthy humans and patients with end-stage renal failure, which acts as a stronger agonist at Mas receptors than Ang 1-7. Chromatographic purification and structural analysis by matrix-assisted laser desorption/ionization time-of-flight/time-of-flight (MALDI-TOF/TOF) revealed an Ang II-like octapeptide, angioprotectin, with the sequence Pro-Glu-Val-Tyr-Ile-His-Pro-Phe, which differs from Ang II in Pro¹ and Glu² instead of Asp¹ and Arg². Pro-Glu-Val-Tyr-Ile-His-Pro-Phe in angioprotectin is most likely generated enzymatically from Ang II. Angioprotectin antagonized the contractile actions of Ang II on rat aortic rings. The physiological antagonism of vasoconstrictor actions of Ang II by angioprotectin is mediated by the Mas receptor. Angioprotectin has a stronger affinity to the Mas receptor than Ang-1-7. Plasma concentrations were ~15% of plasma Ang II concentrations in healthy volunteers and up to 50% in patients with renal failure. A commercially available Ang II antibody did not discriminate between angioprotectin and Ang II; thus, angioprotectin can contribute to Ang II concentrations measured by antibody-based assays. This novel peptide is likely to be a relevant component of the human renin-angiotensin-system.
Collapse
Affiliation(s)
- Vera Jankowski
- Medizinische Klinik IV, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Cardoso CC, Cabrini DA, May M, Bhagat CS, Eleno N, Cayla C, Walther T, Bader M. Functional expression of angiotensinogen depends on splicing enhancers in exon 2. Mol Cell Endocrinol 2011; 332:228-33. [PMID: 21055442 DOI: 10.1016/j.mce.2010.10.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2010] [Revised: 10/21/2010] [Accepted: 10/21/2010] [Indexed: 01/04/2023]
Abstract
Angiotensinogen belongs to the family of serpins and is the only precursor of the potent cardiovascular peptide, angiotensin II, the main effector of the renin-angiotensin system. The gene coding for this protein carries an internal exon (exon 2), the length of which (859 bp) by far exceeds the mean length of internal exons in vertebrates (<300 bp). Here, we show that this essential exon is skipped in about 20% of all transcripts in liver, brain, and kidney of rats and mice. Deletion mutants of exon 2 revealed a 62 bp region located at its 5'-end which is important for its inclusion in the mature angiotensinogen mRNA in transfected COS7 cells. Using an artificial minigene, we defined sequences inside this region as exonic splicing enhancers. These data reveal a novel molecular mechanism important for the renin-angiotensin system with implications in the basic understanding and the therapeutical assessment of cardiovascular diseases.
Collapse
Affiliation(s)
- Cibele C Cardoso
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Str 10, 13125 Berlin, Germany
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Cardoso CC, Alenina N, Ferreira AJ, Qadri F, Lima MP, Gross V, Todiras M, Pesquero JB, Pesquero JL, Bader M. Increased blood pressure and water intake in transgenic mice expressing rat tonin in the brain. Biol Chem 2010; 391:435-41. [PMID: 20180641 DOI: 10.1515/bc.2010.040] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Tonin is a serine proteinase of the kallikrein family that can produce angiotensin II directly from angiotensinogen. To clarify the importance of this enzyme for central nervous control of the cardiovascular system, we generated transgenic mice, TGM(rTon), that express rat tonin in astrocytes. These mice present high levels of tonin mRNA and activity specifically in the brain. As a consequence, TGM(rTon) develop increased blood pressure and water intake. Lisinopril, an ACE inhibitor, is less hypotensive for transgenic mice than for control animals. The AT(1) receptor antagonist candesartan equally lowers blood pressure in transgenic and in control mice. Plasma angiotensin II, but not angiotensin I, is increased in TGM(rTon) compared to the wild type, suggesting release of the peptide from the brain into the circulation. However, AT(1) receptors are desensitized in this transgenic model, as demonstrated by a blunted pressor response to intravenous application of angiotensin II. In conclusion, tonin in the brain may represent an alternative pathway for angiotensin II generation with effects on the cardiovascular system.
Collapse
Affiliation(s)
- Cibele C Cardoso
- Max-Delbrück Center for Molecular Medicine, Berlin-Buch, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, Costa-Fraga FP, Fraga-Silva RA, Cojocaru G, Cohen Y, Bader M, de Almeida AP, Rotman G, Santos RAS. Vascular Relaxation, Antihypertensive Effect, and Cardioprotection of a Novel Peptide Agonist of the Mas Receptor. Hypertension 2010; 56:112-20. [DOI: 10.1161/hypertensionaha.110.152942] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Mas stimulation with angiotensin (Ang)-(1-7) produces cardioprotective effects and vasorelaxation. Using a computational discovery platform for predicting novel naturally occurring peptides that may activate G protein–coupled receptors, we discovered a novel Mas agonist peptide, CGEN-856S. An endothelium- and NO-dependent vasodilating effect was observed for CGEN-856S in thoracic aorta rings of rats (maximal value for the relaxant effect: 39.99±5.034%), which was similar to that produced by Ang-(1-7) (10
−10
to 10
−6
mol/L). In addition, the vasodilator activity of this peptide depended on a functional Mas receptor, because it was abolished in aorta rings of Mas-knockout mice. CGEN-856S appears to bind the Mas receptor at the same binding domain as Ang-(1-7), as suggested by the blocking of its vasorelaxant effect with the Ang-(1-7) analogue
d
-Ala
7
-Ang-(1-7), and by its competitive inhibition of Ang-(1-7) binding to
Mas
-transfected cells. The effect of CGEN-856S on reperfusion arrhythmias and cardiac function was studied on ischemia reperfusion of isolated rat hearts. We found that picomolar concentration of CGEN-856S (0.04 nmol/L) had an antiarrhythmogenic effect, as demonstrated by a reduction in the incidence and duration of reperfusion arrhythmias. Furthermore, acute infusion of CGEN-856S produced a shallow dose-dependent decrease in mean arterial pressure of conscious spontaneously hypertensive rats. The maximum change during infusion was observed at the highest dose. Strikingly, blood pressure continued to drop in the postinfusion period. The results presented here indicate that the novel Mas agonist, CGEN-856S, might have a therapeutic value, because it induces vasorelaxing, antihypertensive, and cardioprotective effects.
Collapse
Affiliation(s)
- Silvia Quintão Savergnini
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Merav Beiman
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Roberto Queiroga Lautner
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Vanice de Paula-Carvalho
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Kyan Allahdadi
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Dalton Caires Pessoa
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Fabiana Pereira Costa-Fraga
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Rodrigo Araújo Fraga-Silva
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Gady Cojocaru
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Yossi Cohen
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Michael Bader
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Alvair Pinto de Almeida
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Galit Rotman
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| | - Robson Augusto Souza Santos
- From the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT-Nanobiofar) (S.Q.S., R.Q.L., V.P.-C., K.A., D.C.P., F.P.C.-F., R.A.F.-S., A.P.A., R.A.S.S.), Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Compugen Ltd (M.Be., G.C., Y.C., G.R.), Tel Aviv, Israel; Max-Delbrück-Center for Molecular Medicine (M.Ba.), Berlin-Buch, Germany
| |
Collapse
|
7
|
Ianzer D, Santos RAS, Etelvino GM, Xavier CH, de Almeida Santos J, Mendes EP, Machado LT, Prezoto BC, Dive V, de Camargo ACM. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca. J Pharmacol Exp Ther 2007; 322:795-805. [PMID: 17475904 DOI: 10.1124/jpet.107.120873] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Angiotensin-converting enzyme (ACE) inhibitors were developed based on proline-rich oligopeptides found in the venom of Bothrops jararaca (Bj) previously known as bradykinin-potentiating peptides (BPPs). However, the exact mechanism of action of BPPs remains unclear. The role of the ACE in the cardiovascular effects of two of naturally proline-rich oligopeptides (Bj-BPP-7a and Bj-BPP-10c) was evaluated in vitro and in vivo. Bj-BPP-7a does not potentiate the cardiovascular response to bradykinin and is a weak inhibitor of ACE C and N sites (K(i) = 40,000 and 70,000 nM, respectively), whereas Bj-BPP-10c is a strong bradykinin potentiator and inhibitor of the ACE C site (K(i) = 0.5 versus 200 nM for N site). Strikingly, both peptides, in doses ranging from 0.47 to 71 nmol/kg, produced long-lasting reduction (>6 h) in the mean arterial pressure of conscious spontaneously hypertensive rats (maximal change, 45 +/- 6 and 53 +/- 6 mm Hg for Bj-BPP-7a and Bj-BPP-10c, respectively). The fall in blood pressure was accompanied by variable degrees of bradycardia. In keeping with the absence of relationship between ACE-inhibitory and antihypertensive activities, no changes in the pressor effect of angiotensin I or in the hypotensive effect of bradykinin were observed at the peak of the cardiovascular effects of both peptides. Our results indicate that the antihypertensive effect of two Bj-BPPs containing the motif Ile-Pro-Pro is unrelated to their ability for inhibiting ACE or potentiating bradykinin (BK), indicating as a major component ACE and BK-independent mechanisms. These results are in line with previous observations suggesting ACE inhibition-independent mechanisms for angiotensin I-converting enzyme inhibitor.
Collapse
Affiliation(s)
- Danielle Ianzer
- Center for Applied ToxinologyCentro de Pesquisa, Inovac çãoe Difusão, Laboratório Especial de Toxinologia Aplicada, Instituto Butantan, Sao Paulo, Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Leeb-Lundberg LMF, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005; 57:27-77. [PMID: 15734727 DOI: 10.1124/pr.57.1.2] [Citation(s) in RCA: 723] [Impact Index Per Article: 38.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Kinins are proinflammatory peptides that mediate numerous vascular and pain responses to tissue injury. Two pharmacologically distinct kinin receptor subtypes have been identified and characterized for these peptides, which are named B1 and B2 and belong to the rhodopsin family of G protein-coupled receptors. The B2 receptor mediates the action of bradykinin (BK) and lysyl-bradykinin (Lys-BK), the first set of bioactive kinins formed in response to injury from kininogen precursors through the actions of plasma and tissue kallikreins, whereas the B(1) receptor mediates the action of des-Arg9-BK and Lys-des-Arg9-BK, the second set of bioactive kinins formed through the actions of carboxypeptidases on BK and Lys-BK, respectively. The B2 receptor is ubiquitous and constitutively expressed, whereas the B1 receptor is expressed at a very low level in healthy tissues but induced following injury by various proinflammatory cytokines such as interleukin-1beta. Both receptors act through G alpha(q) to stimulate phospholipase C beta followed by phosphoinositide hydrolysis and intracellular free Ca2+ mobilization and through G alpha(i) to inhibit adenylate cyclase and stimulate the mitogen-activated protein kinase pathways. The use of mice lacking each receptor gene and various specific peptidic and nonpeptidic antagonists have implicated both B1 and B2 receptors as potential therapeutic targets in several pathophysiological events related to inflammation such as pain, sepsis, allergic asthma, rhinitis, and edema, as well as diabetes and cancer. This review is a comprehensive presentation of our current understanding of these receptors in terms of molecular and cell biology, physiology, pharmacology, and involvement in human disease and drug development.
Collapse
Affiliation(s)
- L M Fredrik Leeb-Lundberg
- Division of Cellular and Molecular Pharmacology, Department of Experimental Medical Science, Lund University, BMC, A12, SE-22184 Lund, Sweden.
| | | | | | | | | |
Collapse
|
9
|
Saifudeen Z, Dipp S, Fan H, El-Dahr SS. Combinatorial control of the bradykinin B2 receptor promoter by p53, CREB, KLF-4, and CBP: implications for terminal nephron differentiation. Am J Physiol Renal Physiol 2005; 288:F899-909. [PMID: 15632413 DOI: 10.1152/ajprenal.00370.2004] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Despite a wealth of knowledge regarding the early steps of epithelial differentiation, little is known about the mechanisms responsible for terminal nephron differentiation. The bradykinin B2 receptor (B2R) regulates renal function and integrity, and its expression is induced during terminal nephron differentiation. This study investigates the transcriptional regulation of the B2R during kidney development. The rat B2R 5′-flanking region has a highly conserved cis-acting enhancer in the proximal promoter consisting of contiguous binding sites for the transcription factors cAMP response element binding protein (CREB), p53, and Krüppel-like factor (KLF-4). The B2R enhancer drives reporter gene expression in inner medullary collecting duct-3 cells but is considerably weaker in other cell types. Site-directed mutagenesis and expression of dominant negative mutants demonstrated the requirement of CREB DNA binding and Ser-133 phosphorylation for optimal enhancer function. Moreover, helical phasing experiments showed that disruption of the spatial organization of the enhancer inhibits B2R promoter activity. Several lines of evidence indicate that cooperative interactions among the three transcription factors occur in vivo during terminal nephron differentiation: 1) CREB, p53, and KLF-4 are coexpressed in B2R-positive differentiating cells; 2) the maturational expression of B2R correlates with CREB/p53/KLF-4 DNA-binding activity; 3) assembly of CREB, p53, and KLF-4 on chromatin at the endogenous B2R promoter is developmentally regulated and is accompanied by CBP recruitment and histone hyperacetylation; and 4) CREB and p53 occupancy of the B2R enhancer is cooperative. These results demonstrate that combinatorial interactions among the transcription factors, CREB, p53, and KLF-4, and the coactivator CBP, may be critical for the regulation of B2R gene expression during terminal nephron differentiation.
Collapse
Affiliation(s)
- Zubaida Saifudeen
- Department of Pediatrics, Tulane University Health Sciences Center, 1430 Tulane Ave., New Orleans, Louisiana 70112, USA
| | | | | | | |
Collapse
|
10
|
McLean PG, Perretti M, Ahluwalia A. Kinin B1receptors as novel anti-inflammatory targets. ACTA ACUST UNITED AC 2005. [DOI: 10.1517/14728222.4.2.127] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
11
|
Merino VF, Silva JA, Araújo RC, Avellar MCW, Bascands JL, Schanstra JP, Paiva ACM, Bader M, Pesquero JB. Molecular structure and transcriptional regulation by nuclear factor-κB of the mouse kinin B1 receptor gene. Biol Chem 2005; 386:515-22. [PMID: 16006238 DOI: 10.1515/bc.2005.061] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Kinins are important mediators in cardiovascular homeostasis, inflammation, and nociception. Two kinin receptors have been described, B 1 and B 2 . The B 1 receptor is normally absent in healthy tissues, but is highly induced under pathological conditions. To understand the molecular mechanism of B 1 receptor up-regulation, we determined the mouse B 1 receptor gene structure, isolated and characterized the promoter region and studied its transcriptional regulation. The mouse B 1 receptor gene contains two exons (with the entire coding region located in the second exon) and a TATA-less promoter with multiple transcription start sites. A 7.7-kbp portion of the 5'-flanking region was examined for promoter activity in vascular smooth muscle cells (VSMCs). A minimal 92-bp fragment, located immediately upstream of the transcription start region, exerted basal and lipopolysaccharide (LPS)-inducible transcription activity in the sense and antisense orientation, and was thereby identified as an enhancer element. Nuclear extracts from VSMCs showed basal and LPS-inducible binding activity of nuclear factor (NF)-kappaB at this sequence. B 1 receptor transcription activation in response to LPS was abolished by cotransfection with IkappaBalphaDeltaN, an NF-kappaB repressor. In summary, our results reveal the structure of the mouse B 1 receptor gene and the involvement of NF-kappaB in the inducible mouse kinin B 1 receptor expression under pathological conditions.
Collapse
Affiliation(s)
- Vanessa F Merino
- Department of Biophysics, Universidade Federal de São Paulo, CEP 04023-062 São Paulo, Brazil
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Cardoso CC, Garrett T, Cayla C, Meneton P, Pesquero JB, Bader M. Structure and expression of two kininogen genes in mice. Biol Chem 2004; 385:295-301. [PMID: 15134344 DOI: 10.1515/bc.2004.025] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AbstractKininogens serve dual functions by forming a scaffold for the assembly of the protein complex initiating the surface-activated blood coagulation cascade and as precursors for the kinin hormones. While rats have three kininogen genes, for mice, cattle, and humans only one gene has been described. Here, we present sequence and expression data of a second mouse kininogen gene. The two genes, kininogen-I and kininogen-II, are located in close proximity on chromosome 16 in a headtohead arrangement. In liver and kidney, both genes are expressed and for each gene three alternative splice variants are synthesized. Two of them are the expected high and low molecular weight isoforms known from all mammalian kininogens. However, for both genes also a third, hitherto unknown splice variant was detected which lacks part of the high molecular weight mRNA due to splicing from the low molecular weight donor site to alternative splice acceptor sites in exon 10. The physiological functions of the six kininogen isoforms predicted by these findings need to be determined.
Collapse
Affiliation(s)
- Cibele C Cardoso
- Max-Delbrück-Center for Molecular Medicine, D-13092 Berlin-Buch, Germany
| | | | | | | | | | | |
Collapse
|
13
|
Santos RAS, e Silva ACS, Maric C, Silva DMR, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SVB, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003; 100:8258-63. [PMID: 12829792 PMCID: PMC166216 DOI: 10.1073/pnas.1432869100] [Citation(s) in RCA: 1334] [Impact Index Per Article: 63.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The renin-angiotensin system plays a critical role in blood pressure control and body fluid and electrolyte homeostasis. Besides angiotensin (Ang) II, other Ang peptides, such as Ang III [Ang-(2-8)], Ang IV [Ang-(3-8)], and Ang-(1-7) may also have important biological activities. Ang-(1-7) has become an angiotensin of interest in the past few years, because its cardiovascular and baroreflex actions counteract those of Ang II. Unique angiotensin-binding sites specific for this heptapeptide and studies with a selective Ang-(1-7) antagonist indicated the existence of a distinct Ang-(1-7) receptor. We demonstrate that genetic deletion of the G protein-coupled receptor encoded by the Mas protooncogene abolishes the binding of Ang-(1-7) to mouse kidneys. Accordingly, Mas-deficient mice completely lack the antidiuretic action of Ang-(1-7) after an acute water load. Ang-(1-7) binds to Mas-transfected cells and elicits arachidonic acid release. Furthermore, Mas-deficient aortas lose their Ang-(1-7)-induced relaxation response. Collectively, these findings identify Mas as a functional receptor for Ang-(1-7) and provide a clear molecular basis for the physiological actions of this biologically active peptide.
Collapse
Affiliation(s)
- Robson A. S. Santos
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Ana C. Simoes e Silva
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Christine Maric
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Denise M. R. Silva
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Raquel Pillar Machado
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Insa de Buhr
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Silvia Heringer-Walther
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Sergio Veloso B. Pinheiro
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Myriam Teresa Lopes
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Michael Bader
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Elizabeth P. Mendes
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Virgina Soares Lemos
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Maria Jose Campagnole-Santos
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Heinz-Peter Schultheiss
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Robert Speth
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
| | - Thomas Walther
- Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, 31270, Minas Gerais, Brazil;
Department of Medicine, Georgetown University,
Washington, DC 20057; Department of Cardiology
and Pneumology, University Hospital Benjamin Franklin, Free University, 12200
Berlin, Germany; Max Delbrück Center, 13125
Berlin, Germany; and Department of Veterinary
and Comparative Anatomy, Pharmacology, and Physiology, Washington State
University, Pullman, WA 99164-6520
- To whom correspondence should be addressed at: Benjamin Franklin Medical
Center, Department of Cardiology and Pneumology, Free University of Berlin,
Hindenburgdamm 30, 12200 Berlin, Germany. E-mail:
| |
Collapse
|
14
|
Mukae S, Itoh S, Aoki S, Iwata T, Nishio K, Sato R, Katagiri T. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens 2002; 16:857-63. [PMID: 12522467 DOI: 10.1038/sj.jhh.1001486] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The use of angiotensin-converting enzyme (ACE) inhibitors to treat hypertension has recently increased. However, their use is associated with a persistent dry cough in a significant percentage of such patients. The present study was designed to assess the contribution of polymorphisms as a genetic marker of ACE-inhibitor-related cough in a Japanese hypertensive population. Genotyping was carried out in 190 patients, 70 with cough and 120 without cough, who had been treated with ACE inhibitors. Polymorphisms of ACE insertion/deletion (I/D), angiotensin II type 1 receptor (1166A/C), type 2 receptor (3123C/A), and bradykinin B2 receptor (-58T/C, exon 1, I/D), were analyzed in these subjects. The TT genotype and T allele of bradykinin B2 receptor (-58T/C) were identified at a significantly higher frequency in the cough (+) patients than in the cough (-) patients. This difference was even more pronounced in women. However, there was no significant relationship between polymorphisms of ACE, angiotensin II receptors, or bradykinin B2 receptor exon 1, and occurrence of ACE-inhibitor-related cough. The transcriptional activity of the bradykinin B2 receptor promoter is involved in the occurrence of cough, and this new marker may provide a valuable tool to detect patients at risk of developing this side effect of ACE inhibitors. In conclusion, Susceptibility to develop cough is associated with a genetic variant of the bradykinin B2 receptor promoter; thus, it may be possible to identify those patients who will develop this adverse reaction to ACE inhibitors in advance.
Collapse
Affiliation(s)
- S Mukae
- Third Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
15
|
Baptista HA, Avellar MCW, Araujo RC, Pesquero JL, Schanstra JP, Bascands JL, Esteve JP, Paiva ACM, Bader M, Pesquero JB. Transcriptional regulation of the rat bradykinin B2 receptor gene: identification of a silencer element. Mol Pharmacol 2002; 62:1344-55. [PMID: 12435802 DOI: 10.1124/mol.62.6.1344] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Kinins are involved in a variety of physiological and pathophysiological processes related to cardiovascular homeostasis, inflammation, blood flow, and nociception. Under physiological conditions, the bradykinin B2 (BKB2) receptor is constitutively expressed and mediates most of kinins' actions. However, the mechanisms regulating BKB2 receptor gene expression are still poorly understood. In this study, 4.6 kilobases of the 5'-flanking region from the rat BKB2 receptor gene were sequenced, and computer analysis revealed several sites for transcriptional factors. Nine promoter mutants were cloned in luciferase reporter gene vectors and transfected in NG108-15 cells and rat aorta vascular smooth muscle cells (VSMCs), showing several positive and negative regulatory elements. A classical silencer with 56 base pairs (bp) caused a decrease in reporter gene activity in NG108-15 cells and VSMCs and was able to inhibit the thymidine kinase promoter. Using electrophoretic mobility shift assay and surface plasmon resonance assay, protein-DNA interactions in the silencer region were determined and specific sets of protein-silencer complexes were detected in both cell types. More intense complexes were observed in the central 21 bp of the silencer and mutation in a putative SRE-1 site strongly impaired the protein-DNA binding. Down-regulation of the BKB2 receptor population in NG108-15 cells promoted by N(6), 2'-O-dibutyryladenosine 3':5'-cyclic monophosphate was paralleled by an increase in the amount of nuclear proteins bound to the silencer sequence showing an inverse relationship between protein-silencer complexes and the transcription of the BKB2 receptor gene. In summary, these data highlight the cell-specific regulation of the BKB2 receptor and the importance of a silencer element present in the regulatory region of the gene.
Collapse
Affiliation(s)
- Heloisa A Baptista
- Center for Development of Experimental Models in Medicine and Biology, Universidade Federal de São Paulo, São Paulo, Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Cayla C, Merino VF, Cabrini DA, Silva JA, Pesquero JB, Bader M. Structure of the mammalian kinin receptor gene locus. Int Immunopharmacol 2002; 2:1721-7. [PMID: 12489785 DOI: 10.1016/s1567-5769(02)00175-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The genes encoding the two kinin receptors, B1 and B2, are closely linked on the same chromosome in human, mouse, and rat. In this article, we present the organisation of the B B2 locus in these mammals. This organisation was obtained by comparing the kinin receptor mRNA sequences of man and mouse with the sequence of chromosomes 14 and 12, respectively. We found that the two genes are located in tandem orientation, separated by only 7.8 kb in mice and 12 kb in humans. The distance of the two genes on rat chromosome 6 was determined by long-range PCR to be 9.5 kb. The organisation of the two genes encoding the kinin receptors is similar in the three species, except that the human B1 gene harbors an additional exon, which may originate from the insertion of an Alu repetitive sequence during evolution. Moreover, the human and rat, but not the murine, B2 genes carry an alternatively spliced exon between exons 2 and 3, termed exon 2b.
Collapse
Affiliation(s)
- Cécile Cayla
- Max-Delbrück-Center for Molecular Medicine (MDC), Robert-Rössle-Strasse 10, D-13092 Berlin-Buch, Germany
| | | | | | | | | | | |
Collapse
|
17
|
Prado GN, Taylor L, Zhou X, Ricupero D, Mierke DF, Polgar P. Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors. J Cell Physiol 2002; 193:275-86. [PMID: 12384980 DOI: 10.1002/jcp.10175] [Citation(s) in RCA: 123] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Bradykinin (BK) is a potent short-lived effector belonging to a class of peptides known as kinins. It participates in inflammatory and vascular regulation and processes including angioedema, tissue permeability, vascular dilation, and smooth muscle contraction. BK exerts its biological effects through the activation of the bradykinin B2 receptor (BKB2R) which is G-protein-coupled and is generally constitutively expressed. Upon binding, the receptor is activated and transduces signal cascades which have become paradigms for the actions of the Galphai and Galphaq G-protein subunits. Following activation the receptor is then desensitized, endocytosed, and resensitized. The bradykinin B1 (BKB1R) is a closely related receptor. It is activated by desArg(10)-kallidin or desArg(9)-BK, metabolites of kallidin and BK, respectively. This receptor is induced following tissue injury or after treatment with bacterial endotoxins such as lipopolysacharide or cytokines such as interleukin-1 or tumor necrosis factor-alpha. In this review we will summarize the BKB2R and BKB1R mediated signal transduction pathways. We will then emphasize the relevance of key residues and domains of the intracellular regions of the BKB2R as they relate to modulating its function (signal transduction) and self-maintenance (desensitization, endocytosis, and resensitization). We will examine the features of the BKB1R gene promoter and its mRNA as these operate in the expression and self-maintenance of this inducible receptor. This communication will not cover areas discussed in earlier reviews pertaining to the actions of peptide analogs. For these we refer you to earlier reviews (Regoli and Barabé, 1980, Pharmacol Rev 32:1-46; Regoli et al., 1990, J Cardiovasc Pharmacol 15(Suppl 6):S30-S38; Regoli et al., 1993, Can J Physiol Pharmacol 71:556-557; Marceau, 1995, Immunopharmacology 30:1-26; Regoli et al., 1998, Eur J Pharmacol 348:1-10).
Collapse
Affiliation(s)
- Gregory N Prado
- Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, USA
| | | | | | | | | | | |
Collapse
|
18
|
Maric C, Casley D, Harris PJ, Alcorn D. Angiotensin II binding to renomedullary interstitial cells is regulated by osmolality. J Am Soc Nephrol 2001; 12:450-455. [PMID: 11181792 DOI: 10.1681/asn.v123450] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Angiotensin II (Ang II) AT(1A) receptors are localized to renomedullary interstitial cells (RMIC) in the inner stripe of the outer medulla but not in the inner medulla. Thus, there seems to be a correlation between decreases in AT(1A) receptor binding to RMIC and increases in interstitial osmolality, suggesting that osmolality is important in determining Ang II binding to RMIC. Cultured RMIC were incubated in media of differing osmolalities (330, 630, 930, and 1230 mOsm/kg H(2)O). (125)I-[Sar(1), Ile(8)] Ang II binding to AT(1A) receptors on RMIC grown in hyperosmolal media (930 mOsm/kg H(2)O) was reduced compared with isoosmolal (330 mOsm/kg H(2)O) media and was progressively reduced with further increases of osmolality. Similar studies were performed using bradykinin (BK) as a control peptide. Binding of the BK receptor ligand (125)I-[HPP-Hoe 140] to B(2) receptors was not affected by varying osmolality of the media. Reverse transcriptase-PCR demonstrated the presence of the mRNA expression for both AT(1A) and B(2) receptors at each osmolality. The conclusion is that osmolality modulates Ang II binding to RMIC; in these cells, this phenomenon is restricted to Ang II as BK binding is not affected. Osmolality-induced changes in Ang II binding may modulate the actions of this peptide on RMIC and provide an important mechanism by which these cells modulate renal medullary function.
Collapse
Affiliation(s)
- Christine Maric
- Department of Anatomy and Cell Biology, University of Melbourne, Victoria, Australia
| | - David Casley
- Department of Medicine (Austin and Repatriation Medical Centre), University of Melbourne, Victoria, Australia
| | - Peter J Harris
- Department of Physiology, University of Melbourne, Victoria, Australia
| | - Daine Alcorn
- Department of Anatomy and Cell Biology, University of Melbourne, Victoria, Australia
| |
Collapse
|
19
|
|
20
|
Goodis HE, Bowles WR, Hargreaves KM. Prostaglandin E2 enhances bradykinin-evoked iCGRP release in bovine dental pulp. J Dent Res 2000; 79:1604-7. [PMID: 11023282 DOI: 10.1177/00220345000790081301] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Mediators produced during inflammation are responsible for hyperalgesia and expression of neurotransmitters and receptors in the nervous system. The production of bradykinin (BK) and the prostaglandins (PGs) may regulate initiation of pain. This study tested the hypothesis that BK and prostaglandin E2 (PGE2) have a positive interaction in evoking neurosecretion of immunoreactive calcitonin gene-related peptide (iCGRP). Bovine dental pulp was prepared and stimulated by the superfusion method with BK alone and in combination with PGE2. Kinin receptor antagonists to bradykinin-evoked release of iCGRP were also tested. Also tested was the hypothesis that dental pulp contains either the B1 or B2 or both BK receptors. Results showed that PGE2 enhanced BK-evoked iCGRP release by more than 50%. Western immunoblots revealed detectable B2 receptor protein with no detectable B1 receptor protein. We conclude that BK evokes iCGRP release from bovine dental pulp which is enhanced by a positive interaction with PGE2. Neurosecretion is evoked from isolated terminals of dental pulp fibers via the bradykinin B2 receptor-dependent mechanism.
Collapse
Affiliation(s)
- H E Goodis
- Division of Endodontics, University of California-San Francisco, 94143-0758, USA.
| | | | | |
Collapse
|
21
|
Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 2000; 36:127-31. [PMID: 10904024 DOI: 10.1161/01.hyp.36.1.127] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The appearance of cough in association with angiotensin-converting enzyme (ACE) inhibitors is thought to be related to bradykinin, and it has been speculated that the elicitation of adverse effects is genetically predetermined. Several polymorphisms of the human bradykinin B(2) receptor gene may be involved in ACE inhibitor-related cough. To investigate this possibility, we identified the -58 thymine (T)/cytosine (C) polymorphism in subjects with ACE inhibitor-related cough. We classified the study population into 4 groups: subjects with and without cough that were treated with ACE inhibitors (n=30/30), nontreated essential hypertensive subjects (n=100), and normotensive subjects (n=100). The -58T/C was genotyped by the polymerase chain reaction single-strand conformation polymorphism method. The frequencies of the CC genotype and C allele of -58T/C were significantly higher in the nontreated hypertensive subjects than in the normotensive subjects. Conversely, the frequencies of the TT genotype and T allele were significantly higher in the subjects with cough than in the subjects without cough. These tendencies were more pronounced in females. Among the promoter assays of the human bradykinin B(2) receptor, -58T was found to have a higher transcription rate than that of -58C. This finding seems to suggest that the transcriptional activity of promoter might be involved in the appearance of ACE inhibitor-related cough. A genetic variant of the bradykinin receptor is involved in the elicitation of ACE inhibitor-related cough. It may be possible to predict the side effects of ACE inhibitors in advance.
Collapse
Affiliation(s)
- S Mukae
- Third Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
22
|
Saifudeen Z, Du H, Dipp S, El-Dahr SS. The bradykinin type 2 receptor is a target for p53-mediated transcriptional activation. J Biol Chem 2000; 275:15557-62. [PMID: 10748162 DOI: 10.1074/jbc.m909810199] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The bradykinin type 2 receptor (BK2) is a developmentally regulated G protein-coupled receptor that mediates diverse actions such as vascular reactivity, salt and water excretion, inflammatory responses, and cell growth. However, little is known regarding regulation of the BK2 gene. We report here that the rat BK2 receptor is transcriptionally regulated by the tumor suppressor protein p53. The 5'-flanking region of the rat BK2 gene contains two p53-like binding sites: a sequence at -70 base pairs (P1 site) that is conserved in the murine and human BK2 genes; and a sequence at -707 (P2) that is not. The P1 and P2 motifs bind specifically to p53, as assessed by gel mobility shift assays. Transient transfection into HeLa cells of a CAT reporter construct driven by 1.2-kilobases of the BK2 gene 5'-flanking region demonstrated that the BK2 promoter is dose dependently activated by co-expression of wild-type p53. Co-expression of a dominant negative mutant p53 suppresses the activation of BK2 by wild-type p53. Promoter truncation localized the p53-responsive element to the region between -38 and -94 base pairs encompassing the p53-binding P1 sequence. Furthermore, p53-mediated activation of the BK2 promoter is augmented by the transcriptional co-activators, CBP/p300. Interestingly, removal of the P2 site by truncation or site-directed deletion amplifies p53-mediated activation of the BK2 promoter. These results demonstrate that the rat BK2 promoter is a target for p53-mediated activation and suggest a new physiological role for p53 in the regulation of G protein-coupled receptor gene expression.
Collapse
Affiliation(s)
- Z Saifudeen
- Department of Pediatrics, Section of Pediatric Nephrology, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
| | | | | | | |
Collapse
|
23
|
Chapter VII Brain kallikrein–kinin system: from receptors to neuronal pathways and physiological functions. HANDBOOK OF CHEMICAL NEUROANATOMY 2000. [DOI: 10.1016/s0924-8196(00)80009-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
24
|
Smock SL, Pan LC, Castleberry TA, Lu B, Mather RJ, Owen TA. Cloning, structural characterization, and chromosomal localization of the gene encoding the human prostaglandin E(2) receptor EP2 subtype. Gene 1999; 237:393-402. [PMID: 10521663 DOI: 10.1016/s0378-1119(99)00323-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Northern blot analysis of human placental RNA using a probe to the 5' end of the human prostaglandin E(2) (PGE(2)) EP2 receptor subtype coding region revealed the existence of a high abundance, low molecular weight transcript. To investigate the origin of this transcript, and its possible relationship to the human EP2 mRNA, we have cloned and characterized the gene encoding the human PGE(2) EP2 receptor subtype, identified transcriptional initiation and termination sites in two tissues (spleen and thymus), and determined its chromosomal localization. The human EP2 gene consists of two exons separated by a large intron, utilizes a common initiation site in both spleen and thymus at 1113 bp upstream of the translation initiation site, and has 3' transcript termini at 1140 bp and 1149 bp downstream of the translation stop site in spleen and thymus respectively. Southern and fluorescence in situ hybridization analysis demonstrated the human EP2 gene to be a single copy gene located in band 22 of the long arm of chromosome 14 (14q22). Though our initial interest in this gene was to investigate potential differential splicing of the human EP2 gene in placenta, this work demonstrates that the atypical transcript observed in placenta probably arises from a distinct, yet related, gene. Knowledge of the sequence, structure, and transcription events associated with the human EP2 gene will enable a broader understanding of its regulation and potential role in normal physiology and disease.
Collapse
MESH Headings
- Amino Acid Sequence
- Base Sequence
- Blotting, Northern
- Blotting, Southern
- Chromosome Banding
- Chromosome Mapping
- Chromosomes, Human, Pair 14/genetics
- Cloning, Molecular
- DNA/chemistry
- DNA/genetics
- Exons
- Female
- Genes/genetics
- Genetic Variation
- Humans
- In Situ Hybridization, Fluorescence
- Introns
- Male
- Molecular Sequence Data
- Placenta/metabolism
- Promoter Regions, Genetic
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptors, Prostaglandin E/genetics
- Receptors, Prostaglandin E, EP2 Subtype
- Sequence Analysis, DNA
- T-Lymphocytes/metabolism
- Tissue Distribution
Collapse
Affiliation(s)
- S L Smock
- Department of Cardiovascular and Metabolic Diseases, Central Research Division, Pfizer, Inc., Eastern Point Road, Groton, CT, USA
| | | | | | | | | | | |
Collapse
|
25
|
Walther DJ, Bader M. Serotonin synthesis in murine embryonic stem cells. BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH 1999; 68:55-63. [PMID: 10320783 DOI: 10.1016/s0169-328x(99)00046-7] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Serotonin (5-HT) is a monoaminergic neurotransmitter involved in various processes in the mammalian nervous system with tryptophan hydroxylase (TPH) as the rate-limiting enzyme in its biosynthesis. Interestingly, there is accumulating evidence that neurotransmitters including 5-HT are directly involved in cleavage divisions and morphogenetic movements during early embryogenesis, even before neurons appear. Clonal cell models will be indispensable for investigating these pre-neuronal actions of neurotransmitter systems. Totipotent embryonic stem (ES) cells represent early embryonic stages, are amenable to genetic manipulations and can be easily induced to differentiate into cells with neuronal and glial properties enabling the recapacitation of neurulation. In this study, we used high-pressure liquid chromatography with fluorometric detection (HPLC-FD) to demonstrate the presence of 5-HT in ES cells. In addition, RNase protection assays and immunohistochemical methods detected TPH mRNA and protein, respectively, confirming the endogeneous production of 5-HT in these cells. Furthermore, TPH protein was detected in mouse zygotes after fertilization. These results indicate that ES cells may be useful for the investigation of neurotransmitters in pre-nervous embryos and their actions during ontogeny.
Collapse
Affiliation(s)
- D J Walther
- Max Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Str. 10, D-13092, Berlin-Buch, Germany
| | | |
Collapse
|
26
|
Voigtländer T, Ganten D, Bader M. Transcriptional regulation of the rat renin gene by regulatory elements in intron I. Hypertension 1999; 33:303-11. [PMID: 9931121 DOI: 10.1161/01.hyp.33.1.303] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Renin catalyzes the rate-limiting step in the enzymatic cascade leading to the vasoactive peptide angiotensin II. Therefore, the activity of the renin-angiotensin system in a tissue is regulated significantly at the level of transcription of the renin gene. Besides transcription factor binding sites in the promoter region, the renin genes of human and rat contain regulatory elements also in intron I. Inclusion of intron I in reporter gene constructs with the renin promoter leads to a marked down-regulation of gene expression in nonrenin expressing 293 human embryonic kidney cells but has hardly any effect in renin-expressing L8 rat skeletal myoblasts. In combination with the cytomegalovirus immediate early gene promoter, the silencing occurs in both cell lines but is less pronounced in L8 cells. By partially deleting intron I in these constructs, we describe 5 negative (I-NRE) and 2 positive (I-PRE) regulatory elements responsible for these effects. Using gel-retardation and methylation-interference assays with 293-nuclear extracts, we detected a pseudo-palindromic protein-binding sequence between position +159 and +171 relative to the transcriptional start site. Binding of transcription factors to this sequence may be important for the tissue-specific silencing of the renin gene outside the juxtaglomerular cells of the kidney.
Collapse
Affiliation(s)
- T Voigtländer
- Max-Delbrück-Center for Molecular Medicine (MDC), Berlin-Buch, Germany
| | | | | |
Collapse
|
27
|
Dean R, Maric C, Aldred GP, Casley D, Zhuo J, Harris P, Alcorn D, Mendelsohn FA. Rat renomedullary interstitial cells possess bradykinin B2 receptors in vivo and in vitro. Clin Exp Pharmacol Physiol 1999; 26:48-55. [PMID: 10027070 DOI: 10.1046/j.1440-1681.1999.02981.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
1. Renomedullary interstitial cells (RMIC), abundant throughout the medulla of the kidney, have been demonstrated to have binding sites for many vasoactive peptides, including atrial natriuretic peptide, endothelin, angiotensin II and bradykinin (BK). These observations would support the hypothesis that interactions between RMIC and vasoactive peptides are important in the regulation of renal function. 2. We aimed to localize the BK B2 receptor binding site to RMIC in vivo and to also demonstrate that these receptors are biologically active in vitro. 3. The present study demonstrates BK B2 binding sites on RMIC of the inner stripe of the outer medulla and the inner medulla of the rat kidney in vivo. 4. We further demonstrate that the BK B2 radioligand [125I]-HPP-Hoe140 specifically bound to rat RMIC in vitro. In addition, reverse transcription-polymerase chain reaction detected the mRNA for the BK B2 receptor subtype in cell extracts. 5. For RMIC in vitro, cAMP levels were increased at 1 min and cGMP levels were increased at 2 min after treatment with 10(-10) and 10(-7) mol/L BK, respectively. Inositol 1,4,5-trisphosphate was increased at 10 s treatment with both 10(-6) and 10(-7) mol/L BK. 6. For RMIC in vitro, BK induced an increase in cell proliferation ([3H]-thymidine incorporation) and an increase in extracellular matrix synthesis (ECM; trans-[35S] incorporation), both effects mediated by BK B2 receptors. 7. We conclude that BK B2 receptors are present on RMIC both in vivo and in vitro. These receptors are coupled to intracellular second messenger systems and, in vitro, their stimulation results in cellular proliferation and synthesis of ECM.
Collapse
Affiliation(s)
- R Dean
- Department of Medicine, University of Melbourne, Austin, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Erdmann J, Hegemann N, Weidemann A, Kallisch H, Hummel M, Hetzer R, Fleck E, Regitz-Zagrosek V. Screening the human bradykinin B2 receptor gene in patients with cardiovascular diseases: Identification of a functional mutation in the promoter and a new coding variant (T21M). ACTA ACUST UNITED AC 1998. [DOI: 10.1002/(sici)1096-8628(19981228)80:5<521::aid-ajmg17>3.0.co;2-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
29
|
Ni A, Chai KX, Chao L, Chao J. Molecular cloning and expression of rat bradykinin B1 receptor. BIOCHIMICA ET BIOPHYSICA ACTA 1998; 1442:177-85. [PMID: 9804950 DOI: 10.1016/s0167-4781(98)00163-8] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The gene encoding rat bradykinin B1 receptor has been cloned by using a partial rat B1 cDNA probe. The rat B1 receptor gene contains two exons and the entire coding region is within the second exon. The 5'-flanking region of the rat B1 receptor gene contains several putative transcriptional regulatory sites including TATA box, cAMP response element, NF-kappaB and AP-1. It showed promoter activity inducible by lipopolysaccharide in vascular smooth muscle cells. Rat B1 receptor mRNA was found to be alternatively spliced and induced by lipopolysaccharide treatment in a wide range of tissues, such as the salivary gland, testis, kidney, lung, heart, prostate and aorta. The deduced rat B1 receptor amino acid sequence is 71% homologous to human and rabbit counterparts, and 89% homologous to the mouse counterpart. The expressed B1 receptor in HEK293 cells displayed a rank order of affinity for the kinin peptides: des-Arg9-BK>Lys-des-Arg9-BK approximately des-Arg9, Leu8-BK>Sar-Tyr-epsilonAhx-Lys-[D-betaNal7, Ile8]-des-Arg9-BK>Sar-Tyr-epsilonAhx-Lys-des-Arg9-BK>>BK>> Hoe140. These results indicate that the cloned gene encodes a functional rat B1 receptor.
Collapse
Affiliation(s)
- A Ni
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA
| | | | | | | |
Collapse
|
30
|
Pesquero JB, Bader M. Molecular biology of the kallikrein-kinin system: from structure to function. Braz J Med Biol Res 1998; 31:1197-203. [PMID: 9876287 DOI: 10.1590/s0100-879x1998000900013] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
The participation of the kallikrein-kinin system, comprising the serine proteases kallikreins, the protein substrates kininogens and the effective peptides kinins, in some pathological processes like hypertension and cardiovascular diseases is still a matter of controversy. The use of different experimental set-ups in concert with the development of potent and specific inhibitors and antagonists for the system has highlighted its importance but the results still lack conclusivity. Over the last few years, transgenic and gene-targeting technologies associated with molecular biology tools have provided specific information about the elusive role of the kallikrein-kinin system in the control of blood pressure and electrolyte homeostasis. cDNA and genomic sequences for kinin receptors B2 and B1 from different species were isolated and shown to encode G-protein-coupled receptors and the structure and pharmacology of the receptors were characterized. Transgenic animals expressing an overactive kallikrein-kinin system were established to study the cardiovascular effects of these alterations and the results of these investigations further corroborate the importance of this system in the maintenance of normal blood pressure. Knockout animals for B2 and B1 receptors are available and their analysis also points to the role of these receptors in cardiovascular regulation and inflammatory processes. In this paper the most recent and relevant genetic animal models developed for the study of the kallikrein-kinin system are reviewed, and the advances they brought to the understanding of the biological role of this system are discussed.
Collapse
Affiliation(s)
- J B Pesquero
- Departamento de Biofísica, Universidade Federal de São Paulo, Brasil.
| | | |
Collapse
|
31
|
Farmer SG, Powell SJ, Wilkins DE, Graham A. Cloning, sequencing and functional expression of a guinea pig lung bradykinin B2 receptor. Eur J Pharmacol 1998; 346:291-8. [PMID: 9652372 DOI: 10.1016/s0014-2999(98)00024-7] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Kinin receptors are classified as B1 and B2 based upon agonist and antagonist potencies and cloning and expression studies. Using sequences from human and rat bradykinin B2 receptors, polymerase chain reaction (PCR) was utilized to isolate cDNA from guinea pig lung. The receptor obtained is predicted to have 372 amino acids and shares > 80% sequence homology with human, rat, rabbit and mouse B2 receptors. In competition binding experiments in Chinese hamster ovary (CHO-K1) cells in which the guinea pig cDNA was expressed, [3H]bradykinin was displaced by kinin receptor ligands with an order of potency consistent with a B2 subtype. In CHO cells expressing the guinea pig receptor, bradykinin caused a concentration 45Ca2+ efflux. A B1 receptor agonist, desArg9-bradykinin, also caused 45Ca2+ efflux but with a potency several orders of magnitude lower than bradykinin. Curiously, several B1 and B2 receptor antagonists induced 45Ca2+ efflux, indicating that this receptor may be coupled differently in CHO cells than in native tissues.
Collapse
Affiliation(s)
- S G Farmer
- Zeneca Pharmaceuticals, Bioscience, B1124 Research Center, Wilmington, DE 19850, USA.
| | | | | | | |
Collapse
|
32
|
Marin Castaño ME, Schanstra JP, Hirtz C, Pesquero JB, Pecher C, Girolami JP, Bascands JL. B2 kinin receptor upregulation by cAMP is associated with BK-induced PGE2 production in rat mesangial cells. THE AMERICAN JOURNAL OF PHYSIOLOGY 1998; 274:F532-40. [PMID: 9580144 DOI: 10.1152/ajprenal.1998.274.3.f532] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
In the rat mesangial cell (MC), activation of the bradykinin B2 receptor (B2R) by bradykinin (BK) is associated with both phospholipase C (PLC) and A2 (PLA2) activities and with inhibition of adenosine 3',5'-cyclic monophosphate (cAMP) formation leading to cell contraction. Because cAMP plays an important role in the regulation of gene expression in general, we investigated the effect of increasing the intracellular cAMP concentration ([cAMP]i) in mesangial cells on the B2 mRNA expression, on the density of B2 receptor binding sites, on the BK-induced increase in both the free cytosolic Ca2+ concentration ([Ca2+]i), and in the prostaglandin E2 (PGE2) production. Forskolin, PGE2, and cAMP analog, 8-bromoadenosine 3',5'-cyclic monophosphate (8-BrcAMP), were used to increase [cAMP]i. Twenty-four-hour treatment with forskolin, PGE2, and 8-BrcAMP resulted in significant increases in B2 receptor binding sites, which were inhibited by cycloheximide. The maximum B2 receptor mRNA expression (160% above control) was observed in cells treated during 24 h with forskolin and was prevented by actinomycin D. In contrast, the D-myo-inositol 1,4,5-trisphosphate (IP3) formation and the BK-induced increase in [Ca2+]i, reflecting activation of PLC, were not affected by increased levels of [cAMP]i. However the BK-induced PGE2 release, reflecting PLA2 activity, was significantly enhanced. These data bring new information regarding the dual signaling pathways of B2 receptors that can be differentially regulated by cAMP.
Collapse
Affiliation(s)
- M E Marin Castaño
- Institut Louis Bugnard, Institut National de la Santé et de la Recherche Médicale U 388, Centre Hospitalier Universitaire Rangueil, Toulouse, France
| | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Rapid developments are expected in the molecular pharmacology of both B1, and B2 types of kinin receptors, since the underlying genetic structures are now known and widely studied. The consequences of kinin receptor duality and physiopathological regulation have not yet been fully appreciated. Medicinal chemistry is also an active front of research in kinin pharmacology, as more effective drugs targeted at kinin receptors are regularly reported. Various complementary molecular approaches (the receptor binding, cloning, immunoreacting, mutagenesis, inactivation, the study of regulation, allelic polymorphisms, and so forth) are expanding our knowledge of the role of kinins in allergy, inflammation, and singularly, renal medicine.
Collapse
Affiliation(s)
- F Marceau
- Centre Hospitalier Universitaire de Québec, Centre de Recherche du Pavillon l'Hôtel-Dieu de Québec, Canada.
| | | |
Collapse
|
34
|
Ishigai Y, Mori T, Ikeda T, Fukuzawa A, Shibano T. Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. THE AMERICAN JOURNAL OF PHYSIOLOGY 1997; 273:H2659-63. [PMID: 9435601 DOI: 10.1152/ajpheart.1997.273.6.h2659] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
To examine whether the bradykinin-nitric oxide (NO) pathway directly participates in the antihypertrophic property of angiotensin-converting enzyme (ACE) inhibitors in congestive heart failure, the effects of bradykinin were studied in rat cultured heart cells. Bradykinin (0.1, 1 nM) prevented the phenylephrine-induced increase in protein/DNA content, an index of hypertrophy of heart cells, and amplified the nitrite/nitrate content in the medium. Perindoprilat (1 microM), an ACE inhibitor, also restrained the progression of cardiac hypertrophy and augmented NO release. These effects of perindoprilat were abolished by HOE-140 (kinin B2 antagonist), N omega-nitro-L-arginine (NO synthase inhibitor), and methylene blue (guanylate cyclase inhibitor). Furthermore, there was a significant correlation between protein/DNA content and nitrite/nitrate content. These results indicate that bradykinin inhibits the progression of cardiac hypertrophy due to the increase in NO release and that perindoprilat produces beneficial effects on cardiac hypertrophy by stimulating the bradykinin-NO pathway.
Collapse
Affiliation(s)
- Y Ishigai
- New Product Research Laboratories II, Tokyo Research and Development Center, Daiichi Pharmaceutical Company, Japan
| | | | | | | | | |
Collapse
|
35
|
Chatterjee TK, Liu X, Davisson RL, Fisher RA. Genomic organization of the rat pituitary adenylate cyclase-activating polypeptide receptor gene. Alternative splicing within the 5'-untranslated region. J Biol Chem 1997; 272:12122-31. [PMID: 9115282 DOI: 10.1074/jbc.272.18.12122] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) elicits its diverse biological actions by interacting with both PACAP-selective type I PACAP receptors (PACAPRs) and type II PACAPRs that do not distinguish between PACAP and vasoactive intestinal polypeptide. Using long distance polymerase chain reaction, we amplified and characterized the entire coding region of the rat type I PACAPR (rPACAPR) gene, which spans 40 kilobases and contains 15 exons. Mapping of the exons and sequencing of all intron-exon boundaries revealed a structural organization of the rPACAPR gene that is very similar to those encoding other members of the calcitonin/secretin/parathyroid hormone receptor family. Southern blot analysis demonstrated a single copy of the rPACAPR gene. A combination of rapid amplification of cDNA ends and reverse transcriptase polymerase chain reaction revealed an unexpected diversity in the rPACAPR mRNA in the 5'-untranslated (5'-UTR) region. Four rPACAPR cDNAs were identified with 5'-UTR sequences that all diverged from the genomic sequence at a site 76 bp upstream of the ATG start codon, where a consensus 3' slice acceptor sequence was located. Sequence analysis of these amplified transcripts demonstrated that they arise by tissue-specific differential usage of four exons in the 5' noncoding region of the rPACAPR gene. This study is the first to elucidate the structural organization of a PACAPR gene and to demonstrate that alternative splicing generates rPACAPR transcripts with unique 5'-UTRs.
Collapse
MESH Headings
- Alternative Splicing
- Amino Acid Sequence
- Animals
- Base Sequence
- Consensus Sequence
- DNA Primers
- Exons
- Genetic Variation
- Introns
- Male
- Models, Structural
- Molecular Sequence Data
- Organ Specificity
- Polymerase Chain Reaction
- Protein Biosynthesis
- Protein Structure, Secondary
- RNA, Messenger/biosynthesis
- Rats
- Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide
- Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I
- Receptors, Pituitary Hormone/biosynthesis
- Receptors, Pituitary Hormone/chemistry
- Receptors, Pituitary Hormone/genetics
- Regulatory Sequences, Nucleic Acid
- Restriction Mapping
- Sequence Homology, Amino Acid
- Sequence Homology, Nucleic Acid
- Transcription, Genetic
Collapse
Affiliation(s)
- T K Chatterjee
- Departments of Pharmacology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
| | | | | | | |
Collapse
|
36
|
Wang DZ, Chao L, Chao J. Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 1997; 29:488-93. [PMID: 9039147 DOI: 10.1161/01.hyp.29.1.488] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Bradykinin binds to its receptor at target organs and exerts a wide spectrum of biological activities including vasodilation, smooth muscle contraction and relaxation, pain, and inflammation. To gain a better insight into the physiological function of this potent vasoactive peptide, we created transgenic mice that harbor the human bradykinin B2 receptor transgene under the control of the Rous sarcoma virus 3'-LTR promoter (RSV-cHBKR). Expression of HBKR in these transgenic mice was identified in the aorta, brain, heart, lung, liver, kidney, uterus, and prostate gland by reverse transcription-polymerase chain reaction Southern blot analysis. Two transgenic mouse lines expressing the human B2 receptor resulted in a significant reduction of blood pressure (84.2 +/- 0.6 mm Hg, n = 28; 76.9 +/- 0.8 mm Hg, n = 24; P < .001) compared with the control littermates (96.9 +/- 0.4 mm Hg, n = 52). Administration of Hoe 140, a bradykinin B2 receptor antagonist, restored the blood pressure of the transgenic mice to normal levels within 1 hour, and the effect diminished within 4 hours. The transgenic mice displayed enhanced blood pressure-lowering effect induced by a bolus intra-aortic injection of kinin and showed increased response in kinin-induced uterine smooth muscle contractility compared with control littermates. These studies show that overexpression of human bradykinin B2 receptor causes a sustained reduction of blood pressure in transgenic mice. They also suggest that the B2 receptor-mediated signal transduction pathway plays a role in blood pressure regulation.
Collapse
Affiliation(s)
- D Z Wang
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425, USA
| | | | | |
Collapse
|
37
|
AbdAlla S, Godovac-Zimmermann J, Braun A, Roscher AA, Müller-Esterl W, Quitterer U. Structure of the bradykinin B2 receptors' amino terminus. Biochemistry 1996; 35:7514-9. [PMID: 8652530 DOI: 10.1021/bi9601060] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The peptide hormone bradykinin exerts important biological functions by binding to and activating bradykinin B2 receptors. B2 receptors belong to the seven transmembrane domain (7TM) receptor family. Cloning of the cDNA sequences for the rat, human, and mouse bradykinin B2 receptor revealed several in-frame AUG triplets as potential initiation sites for translation. Due to "Kozak-like" consensus nucleotides, the AUG codon closest to transmembrane domain 1 was assumed the preferred initiation site for translation, but the real amino terminus of the B2 receptor protein was unknown. The amino terminus of several 7TM receptors has been shown to be essentially involved in receptor activation and/or ligand binding. Therefore we determined the amino terminus of the human and of the rat B2 receptor using domain-specific antipeptide antibodies, amino acid sequence analysis, and in vitro transcription/translation. We report that the human and rat B2 receptor protein start with the methionine which is translated from the first in-frame AUG. This start site extends the known amino terminus of the human and rat B2 receptors by 27 or 30 amino acid residues, respectively. Antibodies raised against a peptide of the initial 27 amino acids of the human B2 receptor stained B2 receptors on intact cells. This finding excludes the existence of a signal sequence for this receptor.
Collapse
Affiliation(s)
- S AbdAlla
- Institute of Physiological Chemistry and Pathobiochemistry, University at Mainz, Germany
| | | | | | | | | | | |
Collapse
|
38
|
Dixon BS, Sharma RV, Dennis MJ. The bradykinin B2 receptor is a delayed early response gene for platelet-derived growth factor in arterial smooth muscle cells. J Biol Chem 1996; 271:13324-32. [PMID: 8662783 DOI: 10.1074/jbc.271.23.13324] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Bradykinin and platelet-derived growth factor (PDGF) are inflammatory mediators important in the response to vascular injury. Based upon the known effect of oncogenic Ras to increase bradykinin receptor expression and the ability of PDGF to stimulate Ras, we examined whether PDGF regulates bradykinin B2 receptor expression in cultured arterial smooth muscle cells. Treatment with PDGF (AB and BB, but not AA) produced a dose- and time-dependent increase in both mRNA (6-7-fold increase at 2-4 h) and cell surface receptors (2-4-fold at 6-12 h) for the B2 receptor. There was a 60-min delay between exposure to PDGF and the initial increase in B2 receptor mRNA. Transcriptional inhibitors, actinomycin D or 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole, completely blocked the increase in B2 receptor mRNA when added up to 60 min after stimulation with PDGF. However, protein synthesis was not required, as treatment with cycloheximide did not block but rather superinduced the PDGF-induced increase in B2 receptor mRNA. Comparison with the immediate early response gene c-fos demonstrated that the increase in B2 receptor mRNA was similarly inhibited by the tyrosine kinase inhibitor, tyrphostin, as well as staurosporine. However, stimulation of c-fos was slightly more sensitive to genistein, while the B2 receptor mRNA was more sensitive to inhibition by the protein kinase C inhibitor, calphostin C. The increase in cell surface B2 receptors were functionally coupled to an increase in phosphoinositide-specific phospholipase C, and the effects of PDGF were selective as there was no increase in either angiotensin II- or arginine vasopressin-induced inositol phosphate formation or intracellular calcium release. Taken together, these results demonstrate that the B2 receptor is a delayed early response gene for PDGF in vascular smooth muscle cells.
Collapse
MESH Headings
- Animals
- Base Sequence
- Bradykinin/pharmacology
- DNA Primers/genetics
- Enzyme Activation/drug effects
- Enzyme Inhibitors/pharmacology
- Gene Expression Regulation/drug effects
- Genes, fos
- Molecular Sequence Data
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Phosphatidylinositol Diacylglycerol-Lyase
- Phosphoric Diester Hydrolases/metabolism
- Platelet-Derived Growth Factor/pharmacology
- Protein Kinase C/antagonists & inhibitors
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Rats
- Receptor, Bradykinin B2
- Receptors, Bradykinin/genetics
- Receptors, Bradykinin/metabolism
Collapse
Affiliation(s)
- B S Dixon
- Department of Medicine, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
| | | | | |
Collapse
|
39
|
Pesquero JB, Lindsey CJ, Paiva AC, Ganten D, Bader M. Transcriptional regulatory elements in the rat bradykinin B2 receptor gene. IMMUNOPHARMACOLOGY 1996; 33:36-41. [PMID: 8856112 DOI: 10.1016/0162-3109(96)00080-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
In an attempt to elucidate the mechanisms underlying the regulation of bradykinin B2 receptor gene expression, the molecular structure of the rat gene including the 5'-flanking region was characterized (J. Biol. Chem. 269: 26920-26925, 1994). In this study we show that the gene spans about 32 kb, including a long first intron of 25 kb. The promoter region drives reporter gene expression in NG108-15 neuroglioma cells, and its expression is upregulated by cAMP, bradykinin, phorbol esters and by coexpression of an activated ras oncogene but not by dexamethasone.
Collapse
Affiliation(s)
- J B Pesquero
- Department of Biophysics, Escola Paulista de Medicina, Säo Paulo, Brazil
| | | | | | | | | |
Collapse
|
40
|
Dixon BS, Dennis M. Interaction between growth factors and kinins in arterial smooth muscle cells. IMMUNOPHARMACOLOGY 1996; 33:16-23. [PMID: 8856109 DOI: 10.1016/0162-3109(96)00076-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Bradykinin receptors are present on vascular smooth muscle cells; however, the regulation and biological function of these receptors is unclear. To address these questions the interaction between growth factors and kinins in cultured arterial smooth muscle cells has been examined. Based upon the data a hypothesis is presented that platelet-derived growth factor (PDGF) upregulates cell surface bradykinin B2 receptors on arterial smooth muscle cells. The biological effect of the increase in B2 receptors is currently unclear but under certain conditions they may enhance mitogenesis. These mitogenic effects however, are strongly opposed by the effects of bradykinin acting via a B1-type of receptor which mediates potent inhibition of growth factor-induced mitogenesis.
Collapse
MESH Headings
- Animals
- Bradykinin/pharmacology
- Cell Division/drug effects
- Cells, Cultured
- Growth Substances/pharmacology
- Kinins/metabolism
- Kinins/pharmacology
- Models, Biological
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Platelet-Derived Growth Factor/pharmacology
- Rats
- Receptor, Bradykinin B2
- Receptors, Bradykinin/drug effects
- Receptors, Bradykinin/metabolism
- Up-Regulation
Collapse
Affiliation(s)
- B S Dixon
- Department of Medicine, University of Iowa College of Medicine, Iowa City, USA
| | | |
Collapse
|
41
|
Bompart G, Tack I, Marin Castaño E, Pesquero JB, Girolami JP, Bascands JL. Cyclosporine A decreases kallikrein and BK2 mRNA expression in the rat renal cortex. IMMUNOPHARMACOLOGY 1996; 32:99-101. [PMID: 8796279 DOI: 10.1016/0162-3109(95)00063-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The effect of subcutaneous injection of cyclosporine (20 mg/kg/day for 3 days) on the expression of kallikrein (Kal) and bradykinin 2 receptor (BK2) mRNA in the rat renal cortex was examined. CsA decreased significantly Kal and BK2 mRNA expression in the kidney cortex. These results indicate that the kallikrein-kinin system may participate in the genesis or the aggravation of the renal haemodynamic effect induced by long term administration of CsA.
Collapse
Affiliation(s)
- G Bompart
- INSERM U388 Institut Louis Bugnard, CHU Rangueil, Toulouse, France
| | | | | | | | | | | |
Collapse
|
42
|
Schinke M, Böhm M, Bricca G, Ganten D, Bader M. Permanent inhibition of angiotensinogen synthesis by antisense RNA expression. Hypertension 1996; 27:508-13. [PMID: 8613194 DOI: 10.1161/01.hyp.27.3.508] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The renin-angiotensin system plays a pivotal role in blood pressure regulation. Recent molecular biological findings led to the new concept that in addition to the classic endocrine system, local tissue systems may also play an important role in cardiovascular diseases such as hypertension. In particular, the brain renin-angiotensin system was shown to influence the central control of blood pressure and is thought to contribute to the hypertensive phenotype of genetically hypertensive rat models. To identify the physiological role of these local systems, we established an antisense strategy to downregulate the expression of the precursor hormone angiotensinogen (AOGEN) in cell culture, which can also be used to establish transgenic rat lines. Plasmids encoding an RNA sequence complementary to the rat AOGEN mRNA under control of different viral and tissue-specific promoters were constructed and transfected into an AOGEN-expressing cell line. A competitive reverse transcription-polymerase chain reaction method was established for the quantification of AOGEN mRNA. Depending on the level of antisense RNA, the expression of the AOGEN gene was reduced down to 22% of control levels. Furthermore, the secretion of AOGEN protein was totally abolished. These results clearly demonstrate that the antisense constructs used are functional in reducing the AOGEN gene expression in vivo and can be used for the production of transgenic rats.
Collapse
Affiliation(s)
- M Schinke
- Max Delbrück Center for Molecular Medicine, Berlin, FRG
| | | | | | | | | |
Collapse
|
43
|
Reissmann S, Schwuchow C, Seyfarth L, Pineda De Castro LF, Liebmann C, Paegelow I, Werner H, Stewart JM. Highly selective bradykinin agonists and antagonists with replacement of proline residues by N-methyl-D- and L-phenylalanine. J Med Chem 1996; 39:929-36. [PMID: 8632416 DOI: 10.1021/jm9301954] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
For further studies on the structural and conformational requirements of positions 2,3, and 7 in the bradykinin sequence, we replaced the proline residues by the more hydrophobic and conformationally restricted N-methyl-L- and D-phenylalanine (NMF). The biological activities of the new analogs were evaluated on rat uterus, guinea pig ileum, and guinea pig lung strip. Receptor binding of the analogs was studied in membranes from rat uterus and guinea pig ileum. Influence of bradykinin analogs on the release of cytokines from mouse spleen cell cultures was also measured. Bradykinin analogs were synthesized by the solid phase method, using Boc strategy on PAM or Merrifield resins. The best results in the formation of the N-methylamide bond were obtained with the coupling reagent PyBrop. In position 7 the substitution of D-Phe by D-NMF, retaining the configuration of the amino acid, converts bradykinin antagonists into agonists. The bradykinin analogs with D-NMF at position 7 gave the highest known tissue selectivity for rat uterus among agonists. [L-NMF(2)]bradykinin has moderate agonist activity on rat uterus but antagonist activity on guinea pig lung strip. It represents a new antagonist for B(2) receptors without any replacement at position 7. The same analog completely inhibits bradykinin-evoked cytokine expression by mononuclear cells.
Collapse
Affiliation(s)
- S Reissmann
- Institute of Biochemistry and Biophysics, Friedrich-Schiller-University-Jena, Germany
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Ball HJ, Shine J, Herzog H. Multiple promoters regulate tissue-specific expression of the human NPY-Y1 receptor gene. J Biol Chem 1995; 270:27272-6. [PMID: 7592987 DOI: 10.1074/jbc.270.45.27272] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Several cDNA clones encoding the human neuropeptide Y-Y1 receptor have been isolated that contain differing sequences at their 5'-ends. The divergence occurs at a splice junction in the 5'-untranslated region, suggesting that at least three forms of the neuropeptide Y-Y1 receptor transcript are generated by alternative splicing at this site. Genomic clones have been isolated that encompass the alternatively spliced 5'-exons. The exons are found 6.4, 18.4, and 23.9 kilobases upstream of exon 2. In the corresponding promoter regions of the various exons, possible response elements for the glucocorticoid receptor, as well as potential binding sites for the AP-1, AP-2, and NF-kappa B transcription factors are found. Analysis of NPY-Y1 transcripts in various cell types demonstrates the tissue-specific activation of the three promoters.
Collapse
Affiliation(s)
- H J Ball
- Garvan Institute of Medical Research, St. Vincent's Hospital, Darlinghurst, Sydney, NSW, Australia
| | | | | |
Collapse
|
45
|
Margolius HS. Theodore Cooper Memorial Lecture. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension 1995; 26:221-9. [PMID: 7635529 DOI: 10.1161/01.hyp.26.2.221] [Citation(s) in RCA: 98] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Kinins can affect many aspects of cellular function, but their roles in human homeostatic mechanisms and disease are just beginning to be understood. In this brief review, some of the interesting new observations about kallikrein-kinin system characteristics, roles in cell behavior, and aberrancy in diseases of relevance to readers interested in hypertension will be discussed. Along the way, questions raised by these observations will be posed. They show that we still have much to learn about the contributions of kinins to human cardiovascular diseases but now have in addition both a strong rationale for asking them and the tools to make them operational.
Collapse
Affiliation(s)
- H S Margolius
- Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, 29425-2251, USA
| |
Collapse
|
46
|
Borkowski JA, Ransom RW, Seabrook GR, Trumbauer M, Chen H, Hill RG, Strader CD, Hess JF. Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 1995; 270:13706-10. [PMID: 7775424 DOI: 10.1074/jbc.270.23.13706] [Citation(s) in RCA: 201] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Mice that are homozygous for the targeted disruption of the gene encoding the B2 bradykinin receptor have been generated. The gene disruption results in a deletion of the entire coding sequence for the B2 receptor. The disruption of the B2 receptor gene has been confirmed by genetic, biochemical, and pharmacological analyses. Mice that are homozygous for the disruption of the B2 receptor gene are fertile and indistinguishable from their littermates by visual inspection. Bradykinin fails to produce responses in pharmacological preparations from ileum, uterus, and the superior cervical ganglia from these mice. Therefore, expression of a single gene appears to be responsible for conferring responsiveness to bradykinin in these tissues.
Collapse
Affiliation(s)
- J A Borkowski
- Department of Molecular Pharmacology & Biochemistry, Merck Research Laboratories, Rahway, New Jersey 07065, USA
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Metzger R, Bader M, Ludwig T, Berberich C, Bunnemann B, Ganten D. Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett 1995; 357:27-32. [PMID: 8001672 DOI: 10.1016/0014-5793(94)01292-9] [Citation(s) in RCA: 113] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We isolated the mas proto-oncogene from a mouse genomic library. Sequence analysis showed that it contains an open reading frame without intervening sequences. The amino acid sequence deduced confirms the seven-transmembrane-domain structure and exhibits 97% and 91% amino acid homology with the rat and the human Mas, respectively. In mice and rats, mas mRNA was detected in the testis, kidney, heart, and in the brain regions: hippocampus, forebrain, piriform cortex, and olfactory bulb. Testicular mas mRNA from rats increases markedly during development, while cerebellar mRNA is high postnatally but completely disappears at later stages. We conclude that the product of the mouse mas gene may be involved in the development of the brain and testis.
Collapse
Affiliation(s)
- R Metzger
- German Institute for High Blood Pressure Research, Heidelberg
| | | | | | | | | | | |
Collapse
|